



## How the test works

**Colon AiQ** is a non-invasive test (liquid biopsy), which is performed in blood and analyzes the methylation profile of 5 clinically validated genetic regions in free circulating genetic material – cfDNA. In the case of colorectal cancer, the methylation profile of these regions changes.

Using this method we can detect these changes at a very early stage of the cancer (even at the stage of advanced adenoma, which is a precancerous lesion) and lead to an early diagnosis.

## The Colon AiQ test has 2 possible results

### 1. Negative signal

A negative result is reassuring and means that we should simply repeat the test next year and generally be consistent with our colorectal cancer screening.

### 2. Positive signal

If the test shows a positive signal, then there is a serious possibility that cancer has developed in the colon and we should definitely contact our gastroenterologist.

# Colon AiQ Test

*Screening for colorectal cancer  
with a simple blood draw with the Colon AiQ Test*



**IQGenomix**  
[www.iqgenomix.com](http://www.iqgenomix.com)






## Colon AiQ Test

**Colon AiQ** allows those who need to be tested, but postpone colonoscopy, to have a first thorough screening through molecular biology techniques and to know if there is a substantial reason to undergo a colonoscopy immediately.

It also gives the option of intermediate screening between colonoscopies in people with confirmed colorectal syndromes or with a family history of cancer, where frequent screening is required, as they are included in high-risk groups for colorectal cancer.

## Who should be tested

According to the international guidelines, colorectal cancer screening is recommended for **all individuals aged 45 and older**. However, in Europe, a significant portion of the population postpones colonoscopy, often due to concerns about its invasive nature. The **Colon AiQ** test provides a non-invasive alternative, encouraging individuals to prioritize bowel health and screening. Based on blood molecular analysis, **Colon AiQ** is the most accurate non-invasive colorectal cancer test available in Europe, offering a convenient and effective solution for early detection and prevention.



## Why should I choose Colon AiQ?



**The most accurate test after colonoscopy:** In Europe, **Colon AiQ** currently stands out as the test with the highest sensitivity (accuracy in detecting positive results) after colonoscopy. This makes it a reliable tool for determining whether there is an immediate need for a colonoscopy, providing a trustworthy option for colorectal cancer screening. With a sensitivity (accuracy in the positive result) of 86% and specificity (accuracy in the negative result) of 92% it is the most accurate test compared to molecular stool tests, as well as cancer marker tests, especially in pre-cancerous stages and early stages of colorectal cancer.

**It can detect advanced adenomas.** **Colon AiQ** is the only molecular test that detects adenomas with such high accuracy. Detecting adenomas is crucial for managing the patient effectively. It helps reduce the risk of cancer development and ensures ongoing follow-up by a gastroenterologist over time, facilitating long-term monitoring and preventive care.



**Easy, quick and non-invasive procedure** for the examinee. It is a very easy procedure for the examinee, requiring only a simple blood draw. There is no pre-work or stress, as the whole process is planned from the moment one orders the test.

**There are clinical studies demonstrating its high accuracy:** **Colon AiQ** is supported by two clinical studies, which prove the high accuracy of the test even in precancerous or very early stages of cancer. In a study with more than 200,000 participants, presented at ESMO 2024, it was shown that **Colon AiQ** can identify asymptomatic patients with neoplastic disease who may benefit from early-stage treatments such as endoscopic or surgical removal.



## Colon AiQ Test VS FIT (Fecal immunochemical test)

Fecal Immunochemical testing had previously been performed in 142 subjects tested with **Colon AiQ**, including 77 with colorectal cancer 16 with advanced adenomas and 49 simple controls.

**Colon AiQ** outperformed fecal immunochemical tests in all stages of CRC (88,3% over 59,7%), especially for stage I (85.7% vs. 28.6%)

**Colon AiQ** is the only molecular test that detects even adenomas with such high accuracy, unlike Immunochemical stool tests, which do not detect adenomas and do not have high sensitivity in early-stage cancers.

